FDA approves first semiannual HIV prevention drug

The Food and Drug Administration has approved a new, first-of-its-kind semiannual HIV prevention medication, Gilead Sciences announced June 18. The company said the injectable drug, called Yeztugo, was nearly 100% effective in clinical trials.